The U.S. Rosacea Market: Size, Trends & Forecasts (2020-2024 Edition)
Foamix Pharmaceuticals Ltd., Galderma, Sol-Gel Technologies Ltd., and Allergan Plc are some of the major players whose company profiling has been done in the report. This segment of the report summarizes business overview, financial overview.
By: Daedal Research
Furthermore, the report also assesses the key opportunities available in the market and summarizes the dynamic forces that are and will be accountable for growth of the industry. Growth of the U.S. rosacea market has also been forecasted for the period 2020-2024, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.
Foamix Pharmaceuticals Ltd., Galderma, Sol-Gel Technologies Ltd., and Allergan Plc are some of the major players whose company profiling has been done in the report.
Foamix Pharmaceuticals Ltd.
Sol-Gel Technologies Ltd
Rosacea is a common disorder associated with skin and most prevalent among people with light skin tone, and mainly affects areas around the chin, cheeks, nose, and forehead. The main characteristic of this disease is solid-bumps and pus-filled pimples.
Rosacea is a common chronic condition of the skin with a high prevalence rate among the U.S. population. It naturally begins at any time after the age of 30 or previously. In some cases, rosacea may also occur on the neck, chest, scalp or ears. Rosacea symptoms and signs include facial flushing, fine red vascular lines, swollen, red eyelids and many more. Currently, more than 16 million populations in the U.S. are suffering from rosacea.
The U.S. rosacea market has grown over the past few years and is projected to grow at a high growth rate on the back of rising incidence of disease, and aging population. The growth in the market will be driven by unhealthy eating habits and environmental factors, rising disposable income, ageing population, escalating healthcare expenditure, high prevalence of rosacea, etc. Yet the market growth is restrained by factors such as lack of awareness and knowledge and stringent government regulations for the approval of new drugs.
For further details, kindly visit :
(Business Development Manager)
Address: 36 SFS Flats
Mail ID - info@daedal-